JP2016519670A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519670A5
JP2016519670A5 JP2016502963A JP2016502963A JP2016519670A5 JP 2016519670 A5 JP2016519670 A5 JP 2016519670A5 JP 2016502963 A JP2016502963 A JP 2016502963A JP 2016502963 A JP2016502963 A JP 2016502963A JP 2016519670 A5 JP2016519670 A5 JP 2016519670A5
Authority
JP
Japan
Prior art keywords
polysorbate
pharmaceutical composition
polypeptide
factor
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519670A (ja
JP6387392B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029010 external-priority patent/WO2014144549A1/en
Publication of JP2016519670A publication Critical patent/JP2016519670A/ja
Publication of JP2016519670A5 publication Critical patent/JP2016519670A5/ja
Application granted granted Critical
Publication of JP6387392B2 publication Critical patent/JP6387392B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502963A 2013-03-15 2014-03-14 第ix因子ポリペプチド製剤 Active JP6387392B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794874P 2013-03-15 2013-03-15
US61/794,874 2013-03-15
PCT/US2014/029010 WO2014144549A1 (en) 2013-03-15 2014-03-14 Factor ix polypeptide formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018119813A Division JP6800916B2 (ja) 2013-03-15 2018-06-25 第ix因子ポリペプチド製剤

Publications (3)

Publication Number Publication Date
JP2016519670A JP2016519670A (ja) 2016-07-07
JP2016519670A5 true JP2016519670A5 (https=) 2017-04-20
JP6387392B2 JP6387392B2 (ja) 2018-09-05

Family

ID=51537733

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2016502963A Active JP6387392B2 (ja) 2013-03-15 2014-03-14 第ix因子ポリペプチド製剤
JP2018119813A Active JP6800916B2 (ja) 2013-03-15 2018-06-25 第ix因子ポリペプチド製剤
JP2019188574A Active JP7591866B2 (ja) 2013-03-15 2019-10-15 第ix因子ポリペプチド製剤
JP2021143100A Withdrawn JP2021183645A (ja) 2013-03-15 2021-09-02 第ix因子ポリペプチド製剤
JP2023147524A Active JP7741145B2 (ja) 2013-03-15 2023-09-12 第ix因子ポリペプチド製剤
JP2025145844A Pending JP2025168477A (ja) 2013-03-15 2025-09-03 第ix因子ポリペプチド製剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018119813A Active JP6800916B2 (ja) 2013-03-15 2018-06-25 第ix因子ポリペプチド製剤
JP2019188574A Active JP7591866B2 (ja) 2013-03-15 2019-10-15 第ix因子ポリペプチド製剤
JP2021143100A Withdrawn JP2021183645A (ja) 2013-03-15 2021-09-02 第ix因子ポリペプチド製剤
JP2023147524A Active JP7741145B2 (ja) 2013-03-15 2023-09-12 第ix因子ポリペプチド製剤
JP2025145844A Pending JP2025168477A (ja) 2013-03-15 2025-09-03 第ix因子ポリペプチド製剤

Country Status (14)

Country Link
US (3) US10588949B2 (https=)
EP (1) EP2968498A4 (https=)
JP (6) JP6387392B2 (https=)
AR (1) AR095527A1 (https=)
AU (4) AU2014228938B2 (https=)
CA (1) CA2899089C (https=)
CL (1) CL2015002719A1 (https=)
EA (1) EA037906B1 (https=)
HK (1) HK1220619A1 (https=)
PH (1) PH12015501854A1 (https=)
SG (3) SG11201505926VA (https=)
TW (4) TWI683666B (https=)
UY (1) UY35463A (https=)
WO (1) WO2014144549A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126265C2 (uk) 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
EP3970737A1 (en) * 2012-01-12 2022-03-23 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
TWI750197B (zh) * 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Fix多肽的應用
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
IL319473A (en) * 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a

Family Cites Families (318)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US5189015A (en) 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
US5077204A (en) 1984-06-21 1991-12-31 Chiron Corporation Yeast endopeptidase for basic amino-acid site cleavage, preparation and use
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4889919A (en) 1986-08-13 1989-12-26 Zymogenetics, Inc. Biologically active PDGF derived A-chain homodimers
DK525384D0 (da) 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
US5157021A (en) 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US4786726A (en) 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
JP2643968B2 (ja) 1988-02-03 1997-08-25 サントリー株式会社 Kex2エンドプロテアーゼ及びその製造方法
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2098261T3 (es) 1989-02-21 1997-05-01 Univ Washington Formas modificadas de hormonas reproductoras.
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US5935815A (en) 1989-10-25 1999-08-10 Katholieke Universiteit Leuven Process for micro biological production of proteins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB9009106D0 (en) 1990-04-23 1990-06-20 3I Res Expl Ltd Processes and intermediates for synthetic antibody derivatives
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5453491A (en) 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
JP4236698B2 (ja) 1990-11-26 2009-03-11 ジェネティックス インスティチュート,リミテッド ライアビリティ カンパニー 宿主細胞でのpaceの発現およびその使用法
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
US5374617A (en) 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
WO1992018628A1 (en) 1991-04-19 1992-10-29 Schering Corporation Subunit of the human interleukin-3 receptor
DK0636173T3 (da) 1991-05-31 1999-05-31 Genentech Inc Behandling af HIV associeret immunthrombocytopenisk purpura
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
US5346991A (en) 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5116753A (en) 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69329795T2 (de) 1992-10-02 2001-07-05 Genetics Institute, Inc. Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5726147A (en) 1993-06-01 1998-03-10 The Scripps Research Institute Human mutant tissue factor compositions useful as tissue factor antagonists
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6518013B1 (en) 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US6310180B1 (en) 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6740734B1 (en) 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
CA2182498A1 (en) 1994-02-01 1995-08-10 William J. Larochelle Fusion proteins that include antibody and nonantibody portions
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5596080A (en) 1994-10-03 1997-01-21 E. I. Du Pont De Nemours And Company Crosslinking processes/agents for zein
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5591573A (en) 1995-04-10 1997-01-07 Alpha Therapeutic Corporation Method and system for testing blood samples
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5579277A (en) 1995-05-01 1996-11-26 Apple Computer, Inc. System and method for interleaving memory banks
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
AU723537B2 (en) 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5840529A (en) 1995-08-02 1998-11-24 Clinical Research Institute Of Montreal Mammalian pro-hormone convertase
DE69628652T3 (de) 1995-09-08 2012-05-03 Genentech, Inc. Vegf-verwandtes protein
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
CA2198968C (en) 1996-03-04 2010-02-09 Toyofumi Masuda Process for production of secretory kex2 derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
IL127558A0 (en) 1996-07-03 1999-10-28 Genentech Inc Hepatocyte growth factor receptor agonists and uses thereof
CA2203745A1 (en) 1996-07-26 1998-01-26 Robert Day Pro-protein converting enzyme
ATE386809T1 (de) 1996-08-02 2008-03-15 Bristol Myers Squibb Co Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
US6159462A (en) 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
IN184589B (https=) * 1996-10-16 2000-09-09 Alza Corp
ZA977959B (en) * 1996-10-16 1998-03-23 Alza Corp Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity.
WO2000007012A1 (en) 1998-07-31 2000-02-10 Carroll Wallace E Method and apparatus for determining anticoagulant therapy factors
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
TW502011B (en) 1997-02-05 2002-09-11 Ajinomoto Kk Process for producing n-long-chain acyl acidic amino acids or salts thereof
ES2340008T3 (es) 1997-02-14 2010-05-27 American Red Cross Expresion de factor ix humano activo en tejido mamario de animales transgenicos.
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
ES2242997T3 (es) 1997-03-14 2005-11-16 Biogen Idec Inc. Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo.
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
ATE285415T1 (de) 1997-06-13 2005-01-15 Gryphon Therapeutics Inc Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6008321A (en) 1998-03-16 1999-12-28 Pharmacopeia, Inc. Universal linker for combinatorial synthesis
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
WO1999056777A1 (en) 1998-05-06 1999-11-11 Temple University - Of The Commonwealth System Of Higher Education REVERSAL OF PROINFLAMMATORY RESPONSE BY LIGATING THE MACROPHAGE FcηRI RECEPTOR
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6355782B1 (en) 1998-07-09 2002-03-12 Baylor College Of Medicine Hypohidrotic ectodermal dyplasia genes and proteins
US6596847B2 (en) 1998-07-15 2003-07-22 Genentech, Inc. Tissue factor protein variants
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE408020T1 (de) 1998-11-06 2008-09-15 Novo Nordisk Healthcare Ag Verfahren zur herstellung von faktor vii
US6280994B1 (en) 1998-11-25 2001-08-28 Zymogenetics, Inc. Zace 1: a human metalloenzyme
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子(igf)i変異体
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6602977B1 (en) 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
IL147269A0 (en) 1999-07-02 2002-08-14 Genentech Inc FVIIa ANTAGONISTS
US6469136B1 (en) 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
JP2001151694A (ja) 1999-09-17 2001-06-05 Takeda Chem Ind Ltd タンパク質粉体の製造法
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
EP1278763B1 (en) 2000-04-28 2007-02-14 Inflazyme Pharmaceuticals, Ltd. 3-nitrogen-6,7-dioxygen steroids and uses related thereto
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
WO2002055110A2 (en) 2000-10-25 2002-07-18 Genzyme Corp Methods for treating blood coagulation disorders
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US7419949B2 (en) 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
KR20040039328A (ko) 2001-09-04 2004-05-10 메르크 파텐트 게엠베하 변형된 펙터 ⅸ
DE60128914T2 (de) 2001-10-05 2008-05-08 Affimed Therapeutics Ag Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
US20030078180A1 (en) 2001-10-24 2003-04-24 Benchmark Research & Technology, Inc. Contaminant-tolerant foaming additive
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2002316574B2 (en) 2002-03-15 2008-05-01 Brandeis University Central airway administration for systemic delivery of therapeutics
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド 変異型Fc領域を含む抗体の同定および作製ならびにその利用法
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
WO2004075923A2 (en) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
WO2004108885A2 (en) 2003-05-06 2004-12-16 Syntonix Pharmaceuticals, Inc. Fc chimeric proteins with anti-hiv drugs
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
CA2522690A1 (en) 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
US7212798B1 (en) 2003-07-17 2007-05-01 Cisco Technology, Inc. Adaptive AGC in a wireless network receiver
JP2005060378A (ja) 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd 生理活性蛋白質含有凍結乾燥製剤
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ, インコーポレイテッド IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
ATE555133T1 (de) 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
EP1684790A4 (en) 2003-11-18 2008-04-30 Iconic Therapeutics Inc HOMOGENEOUS PREPARATIONS OF CHIMERIC PROTEINS
RU2373953C2 (ru) * 2003-12-19 2009-11-27 Ново Нордиск Хелс Кеа Аг Стабилизированная композиция, содержащая полипептид фактора vii
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP1720519A1 (en) 2004-03-04 2006-11-15 Wyeth Lyophilization method to improve excipient crystallization
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Fviii의 부위 지향 변형
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
US8304387B2 (en) 2004-12-15 2012-11-06 Swedish Orphan Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
US20060162552A1 (en) 2005-01-26 2006-07-27 Mohawk Valley Energy Solutions, Inc. Systems and methods for controlling room air quality
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
ES2390354T3 (es) 2005-07-22 2012-11-12 Amgen, Inc Liofilizados de proteínas concentrados, procedimientos y usos
MX2008001865A (es) 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
UA97234C2 (ru) * 2005-11-01 2012-01-25 Уайєт Раствор хлорида натрия для восстановления влагосодержания композиции лиофилизированного фактора ix
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
EP2004683B1 (en) 2006-03-24 2016-05-11 Biogen Hemophilia Inc. Pc5 as a factor ix propeptide processing enzyme
ES2928096T3 (es) 2006-04-04 2022-11-15 Takeda Pharmaceuticals Co Un proceso para la concentración de un polipéptido
ES2349024T3 (es) 2006-04-11 2010-12-21 Csl Behring Gmbh Metodo para aumentar la recuperacion in vivo de polipeptidos terapeuticos.
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
AU2007260185B2 (en) 2006-06-14 2013-01-31 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
WO2008022151A1 (en) 2006-08-15 2008-02-21 Inspiration Biopharmaceuticals, Inc. Prophylactic treatment of hemophilia
US8015841B2 (en) 2006-09-08 2011-09-13 Praxair Technology, Inc. Cryogenic refrigeration system for lyophilization
JP2010503396A (ja) 2006-09-14 2010-02-04 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド アルブミン融合タンパク質
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
AU2008311973B2 (en) 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
AU2008340304B2 (en) 2007-12-21 2016-03-03 Aptevo Biotherapeutics Llc Stabilized factor IX formulations containing trehalose
NZ598193A (en) 2007-12-27 2012-12-21 Baxter Int Chemically Modified Factor IX
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子vii多肽和其用途
CA2721683A1 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ix因子の部位特異的修飾
CN102105582A (zh) 2008-04-21 2011-06-22 诺沃-诺迪斯克有限公司 高糖基化人凝血因子ix
WO2009130602A2 (en) 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
ES2968301T3 (es) 2008-08-05 2024-05-08 Wyeth Llc Liofilización por encima del colapso
CN102119172A (zh) 2008-08-21 2011-07-06 奥克塔法马股份有限公司 重组制备的人类因子viii和ix
BRPI0918988A2 (pt) 2008-09-24 2015-12-01 Stabilitech Ltd métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina.
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
JP5770161B2 (ja) 2009-04-06 2015-08-26 ノヴォ ノルディスク アー/エス 血小板への第viii因子タンパク質の標的送達
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
SI2440241T1 (sl) 2009-06-08 2017-11-30 Amunix Operating Inc. Polipeptidni rastni hormoni in postopki za njihovo izdelavo in uporabo
AU2010263058A1 (en) 2009-06-18 2012-01-12 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
CN102596231B (zh) 2009-06-25 2016-01-20 北卡罗来纳-查佩尔山大学 嵌合因子ⅶ分子
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
EP2470561A1 (en) 2009-08-27 2012-07-04 Novo Nordisk A/S Targeting tissue factor to activated platelets
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
MX2012007676A (es) 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
CN107412737A (zh) 2010-01-19 2017-12-01 韩美科学株式会社 长效g‑csf缀合物的液体制剂
EP2353588B1 (en) 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
WO2011104552A1 (en) * 2010-02-24 2011-09-01 Arecor Limited Stable compositions of factor ix
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
UA126265C2 (uk) * 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
TWI507397B (zh) 2010-09-30 2015-11-11 Toyama Chemical Co Ltd 6-氟-3-羥-2-吡羧醯胺之美洛明鹽
RU2650784C2 (ru) 2011-05-05 2018-04-17 Альбумедикс А/С Варианты альбумина
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP3970737A1 (en) 2012-01-12 2022-03-23 Bioverativ Therapeutics Inc. Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
HRP20200007T1 (hr) 2012-07-11 2020-03-20 Bioverativ Therapeutics Inc. Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
TWI750197B (zh) 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Fix多肽的應用
EP3446700A1 (en) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
DK2968477T3 (da) 2013-03-15 2020-03-09 Bioverativ Therapeutics Inc Faktor viii-polypeptidformuleringer
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
EA202092926A3 (ru) * 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors

Similar Documents

Publication Publication Date Title
JP2016519670A5 (https=)
JP7531564B2 (ja) インスリン分泌性ペプチドの安定な水性非経口医薬組成物
US20230159628A1 (en) Anti-CGRP Antibody Formulation
JP7329571B2 (ja) Il-2医薬組成物
CN102363633B (zh) 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
EP3295952B1 (en) Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
US11534403B2 (en) Liquid pharmaceutical composition
KR20140122213A (ko) 에타너셉트의 안정한 용액 제형
MX383971B (es) Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan.
RU2756619C2 (ru) Жидкая композиция антитела против TNF альфа
KR20180054847A (ko) 양극성 용매에서 안정한 치료 제형들의 제조방법.
KR20170018810A (ko) 안정한 아달리무맙 수성 제제
JP2020512295A (ja) グルカゴン様ペプチド1(glp−1)受容体アゴニスト組成物
CN112546197A (zh) 血管紧张素ii单独或以组合方式用于治疗低血压
JP7221956B2 (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
KR20230121824A (ko) Glp-1/glp-2 이중 효능제의 약학적 조성물
EP3881856B1 (en) Pharmaceutical composition for treating aplastic anemia
WO2018184692A1 (en) Liquid pharmaceutical composition
JP2016535015A5 (https=)
JP6179939B2 (ja) 高濃度γグロブリン製剤の粘度低下方法
JP4707327B2 (ja) ポリペプタイド類の吸着防止剤
WO2016059593A1 (en) Stable injectable composition of protein drugs and process for its preparation
HK40059370A (en) Pharmaceutical composition for treating aplastic anemia
EP2606908A1 (en) Novel pharmaceutical composition for a long acting growth hormone fusion protein (LAGH)
HK40050536A (en) Angiotensin ii alone or in combination for the treatment of hypotension